美沙拉嗪口服联合灌肠治疗轻中度远段溃疡性结肠炎的近期临床疗效分析

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (8): 907-911.

美沙拉嗪口服联合灌肠治疗轻中度远段溃疡性结肠炎的近期临床疗效分析

李鹃, 汪玉兰

皖南医学院弋矶山医院消化内科,芜湖 241001,安徽

收稿日期:2014-04-21 修回日期:2014-07-19 出版日期:2014-08-26 发布日期:2014-08-26
通讯作者: 汪玉兰,女,主任医师,研究方向:炎症性肠病的临床研究。 Tel: 0553-5739321 E-mail: 1065747730@qq.com
作者简介:李鹃,女,硕士,主治医师,研究方向:溃疡性结肠炎的个体化综合治疗。 Tel: 0553-5739321 E-mail: embraco@live.cn
基金资助:
皖南医学院中青年科研基金项目(WK2011F10)

Analysis on clinical efficacy in the near future of mesalazine oral combined with enema for mildly to moderately distal ulcerative colitis

LI Juan, WANG Yu-lan

Department of Gastroenterology,Yijishan Hospital,Wannan Medical College,Wuhu 241001,Anhui,China

Received:2014-04-21 Revised:2014-07-19 Online:2014-08-26 Published:2014-08-26

摘要/Abstract

摘要： 目的观察美沙拉嗪口服联合灌肠治疗轻中度远段溃疡性结肠炎的近期临床疗效及作用机制。方法 40例轻、中度活动期远段溃疡性结肠炎患者,随机分成两组:治疗组20例,口服美沙拉嗪联合美沙拉嗪灌肠液保留灌肠;对照组20例,单用美沙拉嗪口服治疗,疗程均为4周。评价治疗前后两组患者的临床疗效、疾病活动指数(Sutherland DAI),采用Realtime-PCR法检测两组治疗前后肠黏膜MiR-155的表达。结果治疗4周后,治疗组总有效率明显高于对照组(P<0.05);治疗组DAI下降程度明显大于对照组(P<0.05);治疗组肠黏膜MiR-155下降程度明显大于对照组(P<0.01)。结论美沙拉嗪口服联合灌肠治疗活动期轻中度远段溃疡性结肠炎的近期临床疗效优于单用美沙拉嗪,能迅速促进肠道溃疡黏膜愈合,降低DAI,其机制可能通过抑制肠黏膜MiR-155的表达而发挥作用。

关键词: 美沙拉嗪, 溃疡性结肠炎, 临床疗效, MiR-155

Abstract: AIM: To observe clinical efficacy and mechanism of mesalamine oral combined with enema for mildly to moderately distal ulcerative colitis. METHODS: 40 patients with mildly to moderately distal active ulcerative colitis were randomly divided into two groups:trial group (20 cases,mesalamine oral combined with enema)and control group (20 cases, mesalamine oral only),were both treated for 4 weeks. The changes of clinical efficacy and disease activity index(Sutherland DAI)were evaluated before and after the treatment.The expression of MiR-155 in intestinal mucosa was detected by Realtime-PCR.RESULTS: After the treatment for 4 weeks,the trial group total efficiency was better than the control group (P<0.05), the descent range of DAI significantly was higher in trial group than that in control group(P<0.05), the descent range of the expression of MiR-155 in intestinal mucosa significantly was higher in trial group than that in control group(P<0.01). CONCLUSION: The clinical efficacy in the near future of mesalamine oral combined with enema for distal mildly to moderately active ulcerative colitis was superior to that of mesalamine oral only, the intestinal mucosa ulcer heal rapidly and the DAI cut down, by decreasing expression of MiR-155.

Key words: mesalamine, ulcerative colitis, clinical efficacy, MiR-155

中图分类号:

R573.1

李鹃, 汪玉兰. 美沙拉嗪口服联合灌肠治疗轻中度远段溃疡性结肠炎的近期临床疗效分析[J]. 中国临床药理学与治疗学, 2014, 19(8): 907-911.

LI Juan, WANG Yu-lan. Analysis on clinical efficacy in the near future of mesalazine oral combined with enema for mildly to moderately distal ulcerative colitis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 907-911.

参考文献 11

[1]	中国炎症性肠病协作组.3100例溃疡性结肠炎住院病例回顾分析[J].中华消化杂志,2006,26(6):368-372.
[2]	Kornbluth A,Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults : American College of Gastroenterology, Practice Parameters Committee[J].Am J Gastroenterol, 2010, 105(3):501-523.
[3]	中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见[J].胃肠病学,2012,17(12):763-781.
[4]	Frieri G,Pimpo M,Galletti B,et al.Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis[J].Dig Liver Dis,2005,37(2):92-96.
[5]	梁红亮,欧阳钦.罗格列酮联合氨基水杨酸治疗溃疡性结肠炎[J]. 中华内科杂志,2006,45(7):548-551.
[6]	魏晓广,高春献,古劼劼,等.美沙拉嗪口服联合灌肠治疗溃疡性结肠炎120例疗效观察[J]. 医药论坛杂志,2011,32(10):87-88.
[7]	Mehmet C, Jacob TB, Jakob BS, et al.MicroRNAs in inflammatory bowel disease - pathogenesis, diagnostics and therapeutics[J]. World J Gastroenterol, 2012,18(34): 4629-4634.
[8]	Paraskevi A,Theodoropoulos G,Papaconstantinou I,et al.Circulating MicroRNA in inflammatory bowel disease[J]. J Crohns Colitis,2012,6(9):900-904.
[9]	Takagi T,Naito Y,Mizushima K,et al.Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis[J].J Gastroenterol Hepatol,2010, 25(Suppl 1):S129-S133.
[10]	Da-Fan Chen,Gong BD,Xie Q,et al.MicroRNA155 is induced in activated C<inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="Mml1-1009-2501-19-8-907"><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula> T cells of TNBS-induced colitis in mice[J]. World J Gastroenterol,2010,16(7): 854-861.
[11]	Min M,Peng L,Yang Y,et al.MicroRNA-155 is involved in the pathogenesis of ulcerative colitis by targeting FOXO3a[J]. Inflamm Bowel Dis,2014,20(4):652-629.

[1]	许宜琪, 吴茜, 刘书, 刘帆, 邢春燕, 李勤, 何俊俊, 何春玲, 赵咏莉, 高家林. 雷公藤多苷治疗糖尿病肾脏病的临床疗效及抗炎抗纤维化分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1034-1042.
[2]	黄伊婷, 沈爱宗. 阿法替尼治疗肺癌的临床疗效与安全性[J]. 中国临床药理学与治疗学, 2021, 26(4): 474-480.
[3]	林荣芳, 郑玮玮, 刘亦伟, 林翠鸿, 王长连, 黄品芳. 克罗恩病患者英夫利西单抗相关基因多态性与血药浓度及疗效关联性研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 1000-1006.
[4]	王艳红, 蒲君峰, 李红玲, 冯铁新. 锰超氧化物歧化酶模拟物对三硝基苯磺酸诱导溃疡性结肠炎大鼠的保护作用及机制研究[J]. 中国临床药理学与治疗学, 2020, 25(10): 1081-1087.
[5]	闫盼, 施剑飞, 李静, 王晟东, 王姝琪, 汪程鹏, 宋明芬. DRD2和5-HTR2A基因多态性及其交互作用对奥氮平治疗精神分裂症疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(10): 1131-1138.
[6]	宋欣，王雪，周黄红，赵天一. 复方甘草酸苷对PPD患者抗菌肽LL-37的表达及临床预后的影响[J]. 中国临床药理学与治疗学, 2019, 24(4): 458-463.
[7]	郑伟伟，王嘉嘉. 清肠止痢汤和艾灸辅助治疗溃疡性结肠炎的效果及对炎症因子的影响[J]. 中国临床药理学与治疗学, 2019, 24(2): 198-204.
[8]	朱廷富，邹朝春. 百令胶囊对小儿糖尿病肾损伤患儿疗效研究[J]. 中国临床药理学与治疗学, 2018, 23(8): 912-915.
[9]	王梦芝，卫玉光，黄晓玲. 我院美罗培南合理用药分析[J]. 中国临床药理学与治疗学, 2018, 23(8): 937-941.
[10]	曾传莉，胡爱荣，胡耀仁，袁刚，朱德东，石小军. 恩替卡韦联合微生态制剂治疗乙肝肝硬化患者的临床疗效研究[J]. 中国临床药理学与治疗学, 2018, 23(7): 796-801.
[11]	周桃梅，杨上文，汪剑波. 参苓白术散联合美沙拉嗪治疗溃疡性结肠炎的疗效及对NLRP3炎症小体的影响[J]. 中国临床药理学与治疗学, 2018, 23(3): 319-324.
[12]	娄朝胜，吴贤，王海波，张寅，叶乐驰. 益脾养胃汤治疗溃疡性结肠炎相关癌变小鼠的疗效及其机制研究[J]. 中国临床药理学与治疗学, 2018, 23(10): 1088-1096.
[13]	莫亚莉，夏泳，刘义，陶云海，金曼. 石杉碱甲联合艾司西酞普兰对抑郁症临床疗效及认知功能的影响[J]. 中国临床药理学与治疗学, 2017, 22(9): 1040-1044.
[14]	何亚琴，何群峰，赵虞文，郭立新. 肠宁方灌肠联合美沙拉嗪对溃疡性直肠炎患者炎症因子及凝血功能的影响[J]. 中国临床药理学与治疗学, 2017, 22(7): 805-809.
[15]	俞华军，黄凯，张展，郭峭峰，张晓文，张春. 探讨万古霉素硫酸钙联合超短波治疗创伤性骨髓炎临床疗效及安全性[J]. 中国临床药理学与治疗学, 2017, 22(5): 556-559.